A NOVEL CLINICAL CANCER RESEARCH MODEL FOR THE DEVELOPMENT OF YOUR PIPELINE
MEDSIR IS A LEADER IN CANCER CLINICAL RESEARCH COMMITTED TO HELPING BIOTECH COMPANIES IN THE DESIGN OF THE BEST STRATEGIES FOR THE DEVELOPMENT OF THEIR PIPELINE. MEDSIR MAKES THIS POSSIBLE THROUGH A NOVEL RESEARCH MODEL THAT PROVIDES THE BEST PERKS OF ACADEMIC RESEARCH AND THE MAIN ADVANTAGES OF COMPANY-SPONSORED RESEARCH
A NEW MODEL FOR DRUG CLINICAL DEVELOPMENT
MAIN DRAWBACKS OF TRADITIONAL
COMPANY-SPONSORED (CRO-BASED) MODEL
MAIN DRAWBACKS OF TRADITIONAL ACADEMIC/INVESTIGATOR-SPONSORED MODEL
Generation of a network of advisors is costly and time consuming
Delays in accrual and in the generation of data
MEDSIR’s network of oncology experts and KOLs can readily propose ideas for the development of your pipeline free of cost and with no commitment on your end
MEDSIR’s innovative model streamlines clinical research to speed up all processes of a clinical trial
RISK
SOLUTION
Limited capacity to generate clinical development ideas
Limited company involvement in study design and management
MEDSIR can give you access to proposals in different clinical settings from a pantumoral network of specialists in all liquid and solid tumors
MEDSIR’s favors a collaborative approach that considers the strategic interests of companies at all times, including continuous full data access
RISK
SOLUTION
Limited KOL engagement or scientific credibility
Limited capacity to rigorously manage all bureaucratic aspects of clinical research
MEDSIR studies are led by experts in the field, guaranteeing their personal engagement and increasing the consideration of the results in the scientific community
MEDSIR has a cross-functional structure integrating both scientific excellence and a professionalization of operational tasks to industry standards
RISK
SOLUTION
Lack of certainty regarding final CRO costs
Lack of operative reach outside of pre-defined collaborative structures
MEDSIR presents closed, milestone-based budgets where risk is shared
MEDSIR can work with the right sites for each trial anywhere in the world
RISK
SOLUTION
WHAT WE DO FOR HEALTHCARE COMPANIES
Strategic proposal for the clinical development of your drug presentation
-
Your pipeline is introduced to our KOLs
-
Definition of key settings with unmet clinical needs
-
Strategic clinical trial design
-
Collaborative discussion to include your strategic interests
-
Free of charge and with no commitment
1
SYNOPSIS APPROVAL
LOI SIGNED
FINAL CONTRACT
SIGNED
DELIVERY OF CLINICAL STUDY REPORT AND FINAL PUBLICATION
MEDSIR CAN BE OF INTEREST FOR YOU IF...
The pipeline of your biotech/pharma company contains products with potential application in oncology that are in clinical development (or about to start it), and you would like to receive insights from a network of experts and KOLs about the best, most cost-effective strategies to reach the market, with no prior commitment on your end.
-
Exploration of further scenarios to boost the development of your drug
Further development opportunities
-
Clinical trial full management
-
You can join the steering committee
-
Full data access
-
We can share publication rights
Clinical trial execution
-
Initial letter of intent signature
-
Study protocol generation
-
Preliminary operational activities
-
Milestone-based, full-service contract signature
Clinical trial set up
-
Timelines, sites, countries
-
Inclusion of the company’s operational preferences
-
Closed budgets with shared risk
Operational plan and budget construction
5
4
3
2
SCIENTIFIC AND OPERATIONAL EXCELLENCE
MEDSIR can help put young molecules on the right track or allow established molecules to consolidate drug positioning.
We can assist your company in the development of any health-related product, including drugs, diagnostic tools, technologies, etc.
We aim to streamline all types of clinical research by implementing organizational structures that improve human and economic resource efficiency, producing win-win situations for all parties involved.
STRATEGIC
CONSULTANCY
SCIENTIFIC
ADVISING
TRIAL
DESIGN
GLOBAL OPERATIONAL
STRUCTURE
ACCRUAL
OPTIMIZATION
DATA
ANALYSIS
SOME OF OUR CLINICAL TRIALS
SOME CLINICAL EXPERTS COLLABORATING
WITH MEDSIR
JAVIER
CORTÉS
Medical Oncologist
MD, PhD
PETER SCHMID
Medical Oncologist MD, PhD
ANTONIO
LLOMBART
Medical Oncologist
MD, PhD
JORDI
REMON
Medical Oncologist
MD, PhD
MARTA
VAZ-BAPTISTA
Medical Oncologist
MD
JOSEPH GLIGOROV
Medical Oncologist
MD, PhD
FREDERIK MARMÉ
Gynecologist
MD
NOEMÍ REGUART
Medical Oncologist
MD, PhD
MARINA GARASSINO
Medical Oncologist
MD, PhD
PETER
KAUFMAN
Medical Oncologist
MD
JOAN CARLES
Medical Oncologist
MD, PhD
JOSEP MARIA
PIULATS
Medical
Oncologist
MD, PhD
NIKI KARACHALIOU
Medical Oncologist
MD, PhD
JOSÉ
PÉREZ
Medical Oncologist
MD, PhD
ANTONIO
CALLES
Medical Oncologist MD, PhD
JAVIER GARDE
Medical Oncologist
MD
FREQUENTLY ASKED QUESTIONS
GET THE SUPPORT OF OUR NETWORK OF ONCOLOGY KOLS IN THE DEVELOPMENT OF YOUR PIPELINE
MEDSIR HELPS HEALTH COMPANIES NAVIGATE ALL STAGES OF CLINICAL DEVELOPMENT BY OFFERING A NETWORK OF EXPERTS AND A CROSS-FUNCTIONAL SYSTEM FULLY INTEGRATING THE STRATEGIC, SCIENTIFIC AND OPERATIONAL ASPECTS OF CLINICAL RESEARCH. WE GENERATE HIGH-QUALITY SCIENTIFIC EVIDENCE AND FOLLOW THE MOST ADEQUATE DEVELOPMENT STRATEGY TO CONSOLIDATE THE POSITION OF YOUR PRODUCTS IN THE MARKET.
WE CAN ASSIST YOU IN DEVELOPING YOUR INVESTIGATIONAL NEW DRUG!
CONTACT US
If you are looking for the best strategy for the development of your pipeline through an innovative, cross-functional model able to ensure investigator engagement, scientific excellence, and streamlined trial management, fill in the form below and get in touch with us!
We are here to support you!